Suda Pharmaceuticals Ltd EV/EBITDA
What is the EV/EBITDA of Suda Pharmaceuticals Ltd?
The EV/EBITDA of Suda Pharmaceuticals Ltd is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on ASX compared to Suda Pharmaceuticals Ltd
What does Suda Pharmaceuticals Ltd do?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Companies with ev/ebitda similar to Suda Pharmaceuticals Ltd
- C4X Discovery Plc has EV/EBITDA of N/A
- Pacgen Life Science has EV/EBITDA of N/A
- Panther Metals Plc has EV/EBITDA of N/A
- InnovaDerma Plc has EV/EBITDA of N/A
- CryptoStar has EV/EBITDA of N/A
- CHAR Technologies has EV/EBITDA of N/A
- Suda Pharmaceuticals Ltd has EV/EBITDA of N/A
- Dixie Gold has EV/EBITDA of N/A
- Novacyt S.A has EV/EBITDA of N/A
- Bald Eagle Gold has EV/EBITDA of N/A
- Pier 1 Imports Inc has EV/EBITDA of N/A
- Element 29 Resources Inc has EV/EBITDA of N/A
- Standard BioTools Inc has EV/EBITDA of N/A